ºÐÀÚÀ¯ÀüÇнÇÇè½Ç (´Ü±¹´ëÇб³ ºÐÀÚ»ý¹°Çаú)



 À̼º¿í ( 2018-11-14 15:47:56 , Hit : 262
 Keytruda Gets FDA Approval for Hepatocellular Carcinoma

https://www.empr.com/news/keytruda-pembrolizumab-liver-cancer-previously-treated-sorafenib-approval/article/814060/

MPR >  News >  Keytruda Gets FDA Approval for Hepatocellular Carcinoma

Diana Ernst, RPh
November 12, 2018


Keytruda is a programmed death receptor-1 (PD-1) blocking antibody
Keytruda is a programmed death receptor-1 (PD-1) blocking antibody

The Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab; Merck) for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

The approval was based on data from the KEYNOTE-224 study, a single-arm trial in patients with HCC who had disease progression on or after sorafenib or were intolerant to sorafenib; had measurable disease; and had Child-Pugh class A liver impairment. Patients (N=104) were treated with Keytruda 200mg intravenously every 3 weeks until unacceptable toxicity, investigator-assessed confirmed disease progression, or completion of 24 months of therapy; the primary efficacy measures were overall response rate (ORR) and duration of response according to RECIST v1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, as assessed by blinded independent central review.

Results showed an ORR of 17% (95% CI, 11–26), with 1% of patients having a complete response and 16% of patients having a partial response. A duration of response of ¡Ã6 months and ¡Ã12 months was observed in 89% and 56% of patients who responded to treatment (N=18), respectively; the median duration of exposure was 4.2 months.

Continued approval of Keytruda for HCC may be contingent upon verification and description of clinical benefit in confirmatory trials as the indication was approved under the accelerated approval pathway based on tumor response rate and durability of response.



Related Articles
Long-Term Aspirin Use May Reduce Liver Cancer Risk
Lenvima OK'd as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Cabozantinib Improves Survival in Advanced Hepatocellular Cancer


Keytruda, a programmed death receptor-1 (PD-1) blocking antibody, is also approved for the treatment of melanoma, non-small cell lung cancer, head and neck squamous cell cancer, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, microsatellite instability-high cancer, gastric cancer, and cervical cancer.

For more information visit Merck.com.







1267   CRISPR-Cas9 Inhibitors Found in Metagenomics Study  À̼º¿í 2019/02/07 816
1266   [¹ÙÀÌ¿ÀÅäÇÈ] º¯À̰¡ ¸¹Àº ¾ÏÀϼö·Ï ¸é¿ª¿ä¹ý¿¡ Àß ¹ÝÀÀÇÑ´Ù  À̼º¿í 2019/01/15 541
1265   Exosomes Linked to Cancer Spread from Chemoresistant Tumors in Mice  À̼º¿í 2019/01/15 501
1264   Top 10 RNA-Based Biopharmas of 2018  À̼º¿í 2019/01/09 711
1263   Fathers Can Pass Mitochondrial DNA to Children  À̼º¿í 2018/12/26 583
1262   Nonviral CRISPR Technology Developed for Faster, Cheaper T-Cell Engineering  À̼º¿í 2018/12/13 742
1261   Second CRISPR-Modified Pregnancy May Be Underway  À̼º¿í 2018/11/30 282
1260   Human Genome Editing Committee Urges Halt in Germline Editing Trials  À̼º¿í 2018/11/30 286
1259   [¹ÙÀÌ¿ÀÅäÇÈ] Áß±¹, ÃÖÃÊÀÇ À¯ÀüüÆíÁý ¾Æ±â ź»ý  À̼º¿í 2018/11/27 355
  Keytruda Gets FDA Approval for Hepatocellular Carcinoma  À̼º¿í 2018/11/14 262
1257   Novel Two-Pronged Method Targets Cancer Cells¡¯ Telomerase and Chromosomes  À̼º¿í 2018/11/03 276
1256   Expanding the reach of gene editing with a new CRISPR enzyme  À̼º¿í 2018/10/26 298
1255   ºÐÀÚ¼öÁØ ÀÎü °£¼¼Æ÷ Áöµµ óÀ½ ÀÛ¼º  À̼º¿í 2018/10/24 270
1254   RNA-Based Gene Therapy Can Be Turned ON or OFF via Synbio Switches  À̼º¿í 2018/10/18 263
1253   CRISPR Enhancement Cures Genetic Disease in Mice  À̼º¿í 2018/10/10 274
1252   [¹ÙÀÌ¿ÀÅäÇÈ] ±¸°üÀÌ ¸í°ü, CRISPR°¡ ¸¸´ÉÀº ¾Æ´Ï´Ù  À̼º¿í 2018/10/08 424
1251   Checkpoint Inhibitor Generated by Synthetic DNA in Vivo  À̼º¿í 2018/10/06 264
1250   Frances H. Arnold, George P. Smith, and Gregory P. Winter share 2018 Nobel Prize in Chemistry  À̼º¿í 2018/10/04 255
1249   Immunotherapy Pioneers Take 2018 Nobel Prize  À̼º¿í 2018/10/02 280
1248   2018 Lasker Award Winners: Gene Expression Researchers, Propofol Discoverer, Pioneer for RNA Biology, and Women in STEM  À̼º¿í 2018/09/12 557

1 [2][3][4][5][6][7][8][9][10]..[64] [´ÙÀ½ 10°³]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN